Purification and characterization of prokaryotically expressed human interferon-λ2

A system for the production of soluble interferon (IFN)-λ2 was developed by fusing the IFN-λ2, NusA protein, polyhistidine and S peptide genes and then expressing the fused product (Nus-His-S-tagged IFN-λ2) in Escherichia coli. The expressed fusion protein was purified by Ni-NTA affinity chromatography. The fusion tag was removed from recombinant IFN-λ2 by cleavage with enterokinase. N-Terminal sequencing confirmed the identity of the purified protein. When compared with commercial IFN-α2b, IFN-λ2 had similar antiviral activity. The production and characterization of biologically active IFN-λ2 will be beneficial for its potential role in clinical applications.     

Molecular cloning,expression and characterization of Pekin duck interferon-λ

Interferons (IFNs) are the first line of defense against viral infections in vertebrates. Type III interferon (IFN-λ) is recognized for its key role in innate immunity of tissues of epithelial origin. Here we describe the identification of the Pekin duck IFN-λ ortholog (duIFN-λ). The predicted duIFN-λ protein has an amino acid identity of 63%, 38%, 37% and 33% with chicken IFN-λ and human IFN-λ3, IFN-λ2 and IFN-λ1, respectively. The duck genome contains a single IFN-λ gene that is comprised of five exons and four introns. Recombinant duIFN-λ up-regulated OASL and Mx-1 mRNA in primary duck hepatocytes. Our observations suggest evolutionary conservation of genomic organization and structural features implicated in receptor binding and antiviral activity. The identification and expression of duIFN-λ will facilitate further study of the role of type III IFN in antiviral defense and inflammatory responses of the Pekin duck, a non-mammalian vertebrate and pathogen host with relevance for human and animal health.     

Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro

Highlights
1) A comprehensive evaluation method for anti-SARS-CoV-2 drugs was established based on RT-qPCR, TCID₅₀ method, and immunofluorescence.
2) A significant antiviral effect of rHuIFN-α1b was shown with EC₅₀=0.12 IU/mL in Vero cells and EC₅₀=0.52 IU/mL in Calu-3 cells, which was better than rHuIFN-α2b (EC₅₀=0.25 IU/mL in Vero cells and EC₅₀=2.48 IU/mL in Calu-3 cells).
3) rHuIFN-α1b has a good potential in the application of anti-COVID-19 therapy.     

Interaction of IFNλR1 with TRAF6 regulates NF-κB activation and IFNλR1 stability

IFNλR1 is a member of the class II cytokine receptor family, and it associates with IL‐10R2 to form a functional receptor complex, IFNλR. This receptor complex transduces signals from IFNλs (IFNλ1, IFNλ2, and IFNλ3), promoting antiviral and antiproliferative activities similar to those of type I IFNs. In an effort to further understand signal transduction through IFNλR1, we used bioinformatics analysis and identified a tumor necrosis factor receptor‐associated factor 6 (TRAF6)‐binding motif in the intracellular domain of IFNλR1. In subsequent immunoprecipitation and GST pull‐down assays, IFNλR1 was shown to immunoprecipitate with TRAF6 and was pulled down by GST‐TRAF6. Endogenous IFNλR1 and TRAF‐6 interaction implies that these proteins really interact in the cells. This interaction was abrogated upon mutation of the TRAF6‐binding motif in IFNλR1. Furthermore, the interaction between IFNλR1 and TRAF6 inhibited TRAF6‐induced NF‐κB activation, likely due to a reduction in TRAF6 autoubiquitination. Moreover, co‐expression of IFNλR1 with TRAF6 significantly increased the stability of IFNλR1, thereby prolonging its half‐life and enhancing its steady‐state level in cultured cells. J. Cell. Biochem. 113: 3371–3379, 2012. © 2012 Wiley Periodicals, Inc.     

Secretion of human interferon-β 1b by recombinant Lactococcus lactis

Interferon-beta has anti-viral, anti-proliferation and multifunctional immunomodulatory activities and shows promising clinical effects for treatment of inflammatory disorders. The recombinant human interferon-beta (huIFN-beta) 1b was expressed in the food-grade lactic acid bacterium, Lactococcus lactis, using a nisin-controlled gene expression system. huIFN-beta production from recombinant strains (with and without LEISSTCDA propeptide) was approximately 21 and 7 mug l(-1), respectively. Moreover, 95% (former strain) and 88% (latter strain) of total recombinant proteins were secreted into the culture medium. The biological activities of huIFN-beta from recombinant strains revealed similar antiviral activities of 10(7) I.U. mg(-1). These results demonstrate the potential application of recombinant strains as a food grade vehicle to deliver bioactive huIFN-beta in vivo.     

Ran binding protein 9(RanBPM) binds IFN-λR1 in the IFN-λsignaling pathway

Like the type I interferons(IFNs),the recently discovered cytokine IFN-λ displays antiviral,antiproliferative,and proapoptotic activities,mediated by a heterodimeric IFN-λ receptor complex composed of a unique IFN-λR1 chain and the IL-10R2 chain.However,the molecular mechanism of the IFN-λ-regulated pathway remains unclear.In this study,we newly identified RAN-binding protein M(RanBPM) as a binding partner of IFN-λR1.The interaction between RanBPM and IFN-λRl was identified with a glutathione S-transferase pull-down assay and coimmunoprecipitation experiments.IFN-λ1 stimulates this interaction and affects the cellular distribution of RanBPM.However,the interaction between RanBPM and IFN-λR1 does not correlate with their conserved TRAF6-binding sites.Furthermore,we also found that RanBPM is a scaffolding protein with a modulatory function that regulates the activities of IFN-stimulated response elements.Therefore,RanBPM plays a novel role in the IFN-λ-regulated signaling pathway.     

RanBPM结合干扰素λ信号通路中的干扰素受体1

最新发现的干扰素λ表现出抗病毒、抗增殖和促凋亡活性,同I型干扰素一样干扰素λ结合干扰素λ受体复合体后进行信号传递.干扰素受体是由干扰素受体1和白介素10的受体2形成异二聚体,但是干扰素λ信号通路的分子调控机制仍不清楚.本研究分别运用谷胱甘肽巯基转移酶沉淀试验和免疫共沉淀试验证明了Ran蛋白的结合蛋白RanBPM与干扰素λ受体1相互作用.干扰素λ1能够促进干扰素λ受体1与RanBPM的相互作用和影响RanBPM在细胞内的分布.干扰素λ受体1与RanBPM的相互作用与保守的TRAF6的结合位点无关.RanBPM作为一个支架蛋白通过调控干扰素刺激反应元件的活性,是新的调控干扰素λ途径的蛋白.     

Smurf1 protein negatively regulates interferon-γ signaling through promoting STAT1 protein ubiquitination and degradation

Interferons are important cytokines that mediate antiviral, antiproliferative, antitumor, and immunoregulatory activities. However, uncontrolled IFN signaling may lead to autoimmune diseases. Here we identified Smurf1 as a negative regulator for IFN-γ signaling by targeting STAT1 for ubiquitination and proteasomal degradation. Smurf1 interacted with STAT1 through the WW domains of Smurf1 and the PY motif in STAT1 and catalyzed K48-linked polyubiquitination of STAT1. Interestingly, the Smurf1-mediated ubiquitination and degradation did not require STAT1 tyrosine and serine phosphorylation. Subsequently, overexpression of Smurf1 attenuated IFN-γ-mediated STAT1 activation and antiviral immune responses, whereas knockdown of Smurf1 enhanced IFN-γ-mediated STAT1 activation, expression of STAT1 target genes, and antiviral immune responses. Furthermore, IFN-γ stimulation led to enhanced expression of Smurf1. Therefore, our results demonstrate that Smurf1 is a negative feedback regulator for IFN-γ signaling by targeting STAT1 for ubiquitination and proteasomal degradation.     

Production of interferon-β by NB1-RGB cells cultured on peptide-lipid membranes

Cell growth and production of interferon-β (IFN-β) were investigated for normal human skin fibroblast cells (NB1-RGB) cultured on membranes prepared from peptide-lipids containing the arginine-glycine-aspartic acid [Arg-Gly-Asp] (RGD), tyrosine-isoleucine-glycine-serine-arginine [Tyr-Ile-Gly-Ser-Arg] (YIGSR) and arginine-glutamic acid-aspartic acid-valine [Arg-Glu-Asp-Val] (REDV) peptides. Cell density was found to be approximately the same on various peptide-lipid membranes, whereas production of IFN-β depended significantly on the peptide-lipid membranes on which NB1-RGB cells were cultured. The highest production of IFN-β was observed for NB1-RGB cells on REDV-lipid membranes prepared by a casting method (REDV-cast membranes) after 24 hr of cultivation. Specific binding between REDV of REDV-cast membranes and the receptor on the NB1-RGB cells may have caused the specific cell response for the production of IFN-β. This revised version was published online in July 2006 with corrections to the Cover Date.     

Ribavirin enhances interferon-γ levels in patients with chronic hepatitis C treated with interferon-α

Some patients with chronic hepatitis C respond to interferon (IFN)-alpha treatment, and the efficiency can be improved by combining it with ribavirin. The mechanism of this improvement is unknown. To investigate the effects of these two regimens on the immune responses in 51 patients with chronic hepatitis C, we examined the hepatitis C core antigen-specific proliferative response and cytokine production profiles, natural killer (NK) cell cytotoxicity and cytotoxic T cell function during treatment. The results are as follows: (1) both viral clearance and biochemical normalization occurred more frequently in patients receiving combination therapy; (2) the function of NK cells increased after treatment in the responders of both groups (p < 0.05); (3) the level of IFN-gamma produced by hepatitis C core antigen-stimulated peripheral blood mononuclear cells was higher in patients receiving combination therapy, especially in responders; (4) the core antigen-specific proliferative response decreased after treatment, and (5) in addition, the core-specific cytotoxic T cell activities of five responder patients also increased significantly after therapy. In conclusion, enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C.     

YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α

Renal cell carcinoma (RCC) accounts for 80–95 % of kidney tumors, and approximately 30 % of RCC patients have metastatic disease at diagnosis. Conventional chemotherapy is not effective in patients with metastatic RCC (MRCC); therefore, immunotherapy with interferon-α (IFN-α) has been employed to improve survival. However, the response rate of MRCC to IFN-α therapy is low. We previously reported that a signal transducer and activator 3 (STAT3) polymorphism was a useful diagnostic marker to predict the response to IFN-α therapy in patients with MRCC. Therefore, we hypothesized the inhibition of STAT3 in the addition of IFN-α therapy might be useful. Moreover, the blockage of STAT3 itself has been reported to enhance the antitumor effects. However, because IFN-α is thought to elicit its therapeutic effect via enhancement of an antitumor immune response mediated by lymphocytes that can be activated by IFN-α administrations, it is probable that the suppression of STAT3 in vivo relates to autoimmune disorders. In the present study, we found Y-box binding protein-1 (YB-1) was poorly expressed in T lymphocytes, as compared with cancer tissues. YB-1 was reported to have an important effect on the STAT3 pathway. Suppression of STAT3 by YB-1 inhibition did not seem to enhance the potential risk for autoimmune disorders. Moreover, we found sensitivity to IFN-α was increased by YB-1 suppression, and this suppression did not down-regulate IFN-α activation of T lymphocytes.     

从江香猪λ1干扰素基因的克隆及序列分析

[目的]对从江香猪λ1干扰素(interferon-λ1,IFN-λ1)基因进行扩增、克隆和生物信息学分析。[方法]根据Gen Bank登录的猪IFN-λ1基因序列(FJ455508)设计合成特异性引物,通过RT-PCR从淋巴细胞中扩增IFN-λ1基因CDS区并进行克隆和生物信息分析。[结果]从江香猪IFN-λ1基因CDS全长576 bp,共编码191个氨基酸,其分子式为C949H1543N277O270S7,相对分子质量21.38 k Da;该蛋白等电点为9.42,为亲水性蛋白。从江香猪IFN-λ1含有丰富的二级结构,以α-螺旋(64.40%)和无规卷曲(25.65%)为主,蛋白质三级结构中主要以α-螺旋为主,同源性及系统进化树分析结果表明从江香猪与野猪IFN-λ1核苷酸同源性最高(为100%),亲缘关系最近。[结论]从江香猪IFN-λ1基因的克隆和生物信息学分析为进一步研究其抗病毒功能奠定了基础。     

IFN-λ1 in CHO cells: its expression and biological activity

Background

Many studies have investigated the characteristics and biological activities of type III interferon (IFN), finding that it has similar features to type I IFN but also unique actions because it is recognized by a different receptor.

Results

A full-length recombinant human IFN-λ1 (rhIFN-λ1) cDNA was cloned into the pDF expression vector and stably expressed in Flp-In-CHO cells. After four purification steps (ammonium sulfate precipitation, SP Sepharose chromatography, Blue Sepharose 6 fast flow affinity chromatography and molecular sieve chromatography), the rhIFN-λ1 had a purity of about 90% and was found to have the predicted biological activities. The anti-viral activity of rhIFN-λ1 was determined as 10⁶ IU/mg using the vesicular stomatitis virus (WISH-VSV) assay system. The anti-proliferation activity of rhIFN-λ1 was measured using the MTS method and the growth inhibition ratio was 57% higher than that for recombinant human IFN-α2b (rhIFN-α2b) when the rhIFN-λ1 concentration was 1000 IU/ml. rhIFN-λ1 had lower natural killer cell cytotoxicity than rhIFN-α2b.

Conclusion

The Flp-In-CHO system is suitable for stably expressing rhIFN-λ1 that possesses the predicted anti-viral, anti-proliferation and natural killer cell cytotoxicity-promoting activities.

     

Regulation of hepatocyte fate by interferon-γ

Interferon (IFN)-γ is a cytokine known for its immunomodulatory and anti-proliferative action. In the liver, IFN-γ can induce hepatocyte apoptosis or inhibit hepatocyte cell cycle progression. This article reviews recent mechanistic reports that describe how IFN-γ may direct the fate of hepatocytes either towards apoptosis or a cell cycle arrest. This review also describes a probable role for IFN-γ in modulating hepatocyte fate during liver regeneration, transplantation, hepatitis, fibrosis and hepatocellular carcinoma, and highlights promising areas of research that may lead to the development of IFN-γ as a therapy to enhance recovery from liver disease.     

重组人干扰素λ1的表达、纯化及生物活性研究

目的:利用大肠杆菌系统表达重组人Ⅲ型干扰素λ1(rhIFN-λ1),并进行纯化,以比较其与重组人干扰素-α2b(rhIFN-α2b)生物学活性的差异。方法:密码子优化的rhIFN-λ1基因与pET-44a载体连接构建原核表达质粒,在大肠杆菌BL21(DE3)中表达,表达产物经系列层析纯化;采用细胞病变抑制法比较纯化的rhIFN-λ1与rhIFN-α2b、市售rhIFN-λ1的抗病毒活性;采用MTS法比较这些干扰素的抗肿瘤细胞增殖活性。结果:基因优化后的rhIFN-λ1在大肠杆菌中得以高效表达,用所建立的纯化工艺可制备得到纯度达95.7%的rhIFN-λ1;rhIFN-λ1的抗病毒比活性为3.2×105 U/mg,比市售rhIFN-λ1的比活性(1.1×105 U/mg)略高,抗肿瘤细胞增殖活性为rhIFN-α2b的1.7倍。结论:获得的rhIFN-λ1具有剂量依赖的抗病毒活性和抗增殖活性,其抗病毒活性比市售rhIFN-λ1略高,抗细胞增殖活性高于rhIFN-α2b,提示rhIFN-λ1有较大的应用前景。